Endothelial dysfunction is a critical factor in the development of atherothrombosis and vascular disease. Drs. Ganz and Vita, along with Verma, Buchanan, and Anderson, have shown that endothelial function is dynamically regulated and that various injuries, such as atherosclerosis, hypertension, diabetes, and aging, significantly impair the endothelium's vasodilator, anti-inflammatory, and antithrombotic functions. Recent studies indicate that endothelial dysfunction in coronary and peripheral arteries occurs before clinical manifestations of atherothrombosis. Current methods for assessing endothelial function include testing with endothelium-dependent vasodilators like acetylcholine or evaluating arterial occlusion followed by functional assessment. While ultrasound has been used for noninvasive measurement, it has limitations in assessing all aspects of endothelial function, including antithrombotic, metabolic, and anti-inflammatory properties. Future research should focus on developing better noninvasive techniques to evaluate endothelial function in various arteries and identifying biomarkers that accurately reflect endothelial dysfunction. C-reactive protein is suggested as a potential biomarker, but current studies do not strongly support its specific correlation with endothelial dysfunction. There is a need for improved imaging and biomarkers to detect early and progressive endothelial dysfunction. Additionally, information on interventions that reverse inflammation, hyperlipidemia, hypertension, and diabetes to improve endothelial function and prevent atherothrombosis is essential. While challenges remain, advancements in noninvasive testing and understanding endothelial dysfunction could significantly enhance the diagnosis and prognosis of vascular diseases.Endothelial dysfunction is a critical factor in the development of atherothrombosis and vascular disease. Drs. Ganz and Vita, along with Verma, Buchanan, and Anderson, have shown that endothelial function is dynamically regulated and that various injuries, such as atherosclerosis, hypertension, diabetes, and aging, significantly impair the endothelium's vasodilator, anti-inflammatory, and antithrombotic functions. Recent studies indicate that endothelial dysfunction in coronary and peripheral arteries occurs before clinical manifestations of atherothrombosis. Current methods for assessing endothelial function include testing with endothelium-dependent vasodilators like acetylcholine or evaluating arterial occlusion followed by functional assessment. While ultrasound has been used for noninvasive measurement, it has limitations in assessing all aspects of endothelial function, including antithrombotic, metabolic, and anti-inflammatory properties. Future research should focus on developing better noninvasive techniques to evaluate endothelial function in various arteries and identifying biomarkers that accurately reflect endothelial dysfunction. C-reactive protein is suggested as a potential biomarker, but current studies do not strongly support its specific correlation with endothelial dysfunction. There is a need for improved imaging and biomarkers to detect early and progressive endothelial dysfunction. Additionally, information on interventions that reverse inflammation, hyperlipidemia, hypertension, and diabetes to improve endothelial function and prevent atherothrombosis is essential. While challenges remain, advancements in noninvasive testing and understanding endothelial dysfunction could significantly enhance the diagnosis and prognosis of vascular diseases.